VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Minister of Health and Wellness Dr. Michael Darville said yesterday that a bill that would integrate the prescription drug ...

The government’s top vaccine official, working under Health Secretary Robert F. Kennedy Jr., restricted the approval of two ...

Why and how does exercise reduce cancer risk, and what should everyone know about incorporating exercise programs in their ...